Skip to main content
ENSC logo

Ensysce Biosciences, Inc.

ENSCNASDAQHealthcareBiotechnology

$0.60Today:- (-)1Y −76.74%

As of Oct 15, 2026 close

Market cap
$7.79M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.23$2.75
Volume (live)
-
Avg. volume (3M)
592.51K

Ensysce Biosciences (ENSC) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Ensysce Biosciences used $7.81M of cash in operating activities and spent $123.64K on capital expenditures. That left free cash flow of −$7.93M.

Ensysce Biosciences Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Ensysce Biosciences, Inc. (ENSC) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Mar 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income-10.18-7.99-10.63-24.21-29.15-29.15-0.160.37-1.34-0.03
Depreciation & Amortization0.011.200.000.000.000.000.000.000.000.00
Deferred Income Tax0.000.000.000.000.00--2.450.000.000.00
Stock Based Compensation0.180.110.881.070.120.120.180.000.000.00
Change in Working Capital1.52-0.85-0.955.48-1.30-1.300.192.460.27-0.10
Change in Accounts Receivable-0.30-0.030.180.16-0.44-0.440.170.00-0.170.00
Change in Inventory0.000.000.000.000.00--0.170.000.000.00
Change in Accounts Payable1.82-0.58-1.232.64-1.42-1.421.180.000.320.11
Change in Other Working Capital0.00-0.280.111.820.567.33-1.002.460.13-0.21
Other Operating Activities0.670.03-0.09-0.2322.097.331.008.17-0.32-0.23
Net Cash from Operating Activities-7.81-7.50-10.78-17.89-8.24-8.24-1.2510.99-1.24-0.25
Investing Activities
Capital Expenditures-0.120.000.000.000.00-0.000.000.000.00
Purchases of Investments0.000.000.000.000.00-0.00-0.570.00-200.00
Other Investing Activities0.000.000.000.000.00-183.400.000.840.00
Net Cash from Investing Activities-0.120.000.000.000.00-183.40-0.570.84-200.00
Financing Activities
Debt Repayment0.00-0.860.61-2.0013.91-0.471.100.570.000.00
Common Stock Issued5.8712.219.053.786.636.630.00-0.01-0.03202.34
Common Stock Repurchased0.000.000.000.000.00-0.00-11.580.000.00
Other Financing Activities2.876.64-0.90-0.55-0.23-0.490.000.000.000.00
Net Cash from Financing Activities8.749.888.768.7720.3120.311.10-11.03-0.03202.34
Summary
Effect of Forex Changes on Cash0.000.000.000.000.00--183.400.000.000.00
Net Change in Cash0.812.38-2.02-9.1212.0712.07-0.15-0.60-0.432.09
Cash at Beginning of Period3.501.123.1512.260.190.190.341.662.090.00
Cash at End of Period4.313.501.123.1512.2612.260.191.061.662.09
Free Cash Flow-7.93-7.50-10.78-17.89-8.24-8.24-1.2510.99-1.24-0.25
Supplemental Disclosures
Income Taxes Paid-0.000.000.00-0.000.00---

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Ensysce Biosciences Cash Flow

What is Ensysce Biosciences's free cash flow?

Ensysce Biosciences had negative free cash flow of $7.93M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$7.81M minus $123.64K of capital expenditures.

How much does Ensysce Biosciences spend on capital expenditures?

Ensysce Biosciences spent $123.64K on capital expenditures in fiscal 2025.

Does Ensysce Biosciences pay dividends or buy back shares?

Ensysce Biosciences's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition